We read with keen interest a recent article in ChosunBiz that highlights a critical conversation happening in the digital health space. In the piece, industry expert Park pinpoints a regulatory challenge that many of us in the field know all too well:
“To pass regulatory review, products are designed conservatively, which makes it hard for patients to immediately feel they are innovative… Society needs to recognize digital therapeutics as medical practice and provide institutional support so that prescriptions can be actively made.”
At Newel Health, this quote resonated deeply with us because it captures the central tension of Digital Therapeutics (DTx) development today: the tug-of-war between the clinical rigor required for approval and the engaging user experience required for adoption.
The “Boring App” Trap
Park’s observation is sharp. To satisfy regulatory bodies (like the FDA, EMA, or MFDS), developers often strip away the “bells and whistles” to ensure the mechanism of action is isolated, predictable, and safe. The unintended result? “Dry” medical applications that feel like homework rather than helpful tools.
If a patient opens a prescribed app and it feels outdated or purely clinical, their engagement drops. And in digital medicine, engagement is efficacy. If they don’t use it, it can’t work.
Newel’s Philosophy: The Power of “And”
We believe that safety and innovation are not mutually exclusive. In fact, the future of DTx lies in the ability to deliver both.
- Safety First: We never compromise on clinical evidence. Our solutions, like Soturi for Parkinson’s and Amicomed for hypertension, are built on robust scientific foundations.
- Innovation Always: We use “Human-Centered Design” to ensure that rigorous medical protocols are delivered through interfaces that feel intuitive, modern, and empathetic.
Rigor need not mean uninspiring. By leveraging adaptive algorithms—like those in our H. Core platform—we can create personalized experiences that satisfy regulatory safety standards while still feeling novel and responsive to the patient.
Beyond the App: The Need for Institutional Pathways
The second part of Park’s insight is equally vital: “Society needs to recognize digital therapeutics as medical practice.”
For DTx to scale, we need more than just good apps; we need a healthcare ecosystem that knows how to handle them. This means:
- Prescription Pathways: Doctors need clear guidelines on how to prescribe digital solutions alongside traditional pharmaceuticals.
- Reimbursement Models: Payers must value digital outcomes as highly as pharmacological ones.
- Clinician Trust: Providers need real-world evidence to feel confident that the “app” they are prescribing is safe and effective.
The Road Ahead
Regulatory agencies are beginning to adapt, recognizing that software is different from a pill. It evolves. It learns. It changes behaviors.
We are optimistic. As frameworks evolve to allow for more iterative and adaptive approvals, developers will be freed to design not just for regulatory checkboxes, but for the true human experience.
Until then, Newel Health will continue to bridge the gap—proving that a digital therapeutic can be a serious medical device and a delightful daily companion, all at once.
